P2Y12 receptor antagonists in acute coronary syndrome: Clinical implications of pharmacologic and pharmacogenetic differences

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 3, 2011, Pages 207-214

  Singh, Mukesh ^a   Adigopula, Sasikanth ^a   Ahmad, Niaz ^a   Arora, Rohit ^a   Khosla, Sandeep ^a  

^a The Chicago Medical College   (United States)

Author keywords

Antiplatelet therapy; Novel agents

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; ELINOGREL; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG METABOLISM; DYSPNEA; HUMAN; LOADING DRUG DOSE; PATENT; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 80053507158     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011797376960     Document Type: Review

References (96)

1. Serebruany VL. Aggressive antiplatelet strategies: Time to reconsider. Editorial. Eur Heart J 2007; 28: 2183-4.
2. Siller-Matula J, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-93.
3. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: Past, present and future. Nat Clin Pract Cardiovasc Med 2008; 5: 766-80.
4. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009; 103(3 Suppl): 4A-10A. DOI 10.1016/j.amjcard.2008.11.017
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
6. Gent M. "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE),". Lancet 1996; 348(9038): 1329-1339.
7. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247. DOI 10.1016/j.jacc.2007.10.001
8. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007; 50: e1-e157. DOI 10.1016/j.jacc.2007.02.013
9. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21- e181. DOI 10.1161/CIRCULATIONAHA 108.191261
10. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: An updated meta-analysis. Thromb Haemost 2010; 103: 841-8.
11. Algaier I, Jakubowski JA, Asai F, Von-kugelgen I. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 2008; 6: 1908-14.
12. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clinic Pharmacol 2010; 50: 126-42.
13. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/ OFFSET study. Circulation 2009; 120: 2577-85.
14. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008; 156 Suppl: S10-S15.
15. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008; 156: S23-S28.
16. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-7.
17. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407-13.
18. Gretler D, Conley P, Andre P, Jurek M, Pandey A, Romanko K, et al. "First In Human" experience with prt060128, a new directacting, reversible, P2Y12 inhibitor for iv and oral use [abstract]. J Am Coll Cardiol 2007; 49: 326A.
19. Gurbel PA, Bliden KP, Hiatt BL, & O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107(23): 2908-13.
20. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145(2): 239-47.
21. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all? Circulation 2006; 114(22): e600-e606.
22. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 2006; 27(6): 647-54.
23. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49(14): 1505-16.
24. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115(6): 708-16.
25. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic vents in patients with acute myocardial infarction. Circulation 2004; 109(25): 3171-5.
26. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high posttreatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45(9): 1392-6.
27. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results from the CREST Study. J Am Coll Cardiol 2005; 46(10): 1827-32.
28. Hochholzer W, Trenk D, Bestehorn P, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48(9): 1742-50.
29. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug eluting stent thrombosis. J Am Coll Cardiol 2007; 49(24): 2312-7.
30. Marin F, Gonzalez-Conejero R, Capranzano P, Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009; 54: 1041-57.
31. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005; 45(8): 1157-64.
32. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116: 491-497.
33. Von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112(19): 2946-50.
34. Von Beckerath N, Von Beckerath O, Koch W, Eichinger M, Schömig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005; 16(3): 199-204.
35. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
36. Angiolillo DJ, Fernandez Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807C/T polymorphism of the glycoprotein Ia Gene. Am J Cardiol 2005; 96: 1095-9.
37. Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Romero-Barra M, et al. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thromb Haemost 2007; 97: 212-7.
38. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15: 89-93.
39. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-60.
40. Smith SM, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P, et al. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 2005; 16: 340-5.
41. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360(9340): 1155-62.
42. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352(21): 2211-21.
43. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-9.
44. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
45. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-7.
46. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32.
47. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8.
48. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-9.
49. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meveau N, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
50. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
51. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
52. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373: 309-17.
53. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-22.
54. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009; 103: 806-11.
55. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-36.
56. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirintreated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-52.
57. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-7.
58. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1- year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents. J Am Coll Cardiol 2008; 51: 1925-34.
59. Mega JL, Wiviott SD, Shen L, Walker JR, Simon T, Antmann EA, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-9.
60. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON- TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010; 376(9749): 1312-9.
61. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. for the PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376(9749): 1320-8.
62. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: A meta-analysis. Pharmacogenomics J 2010; published online March 30. DOI: 10.1038/tpj.2010.21.
63. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic metaanalysis. J Am Coll Cardiol 2010; 56: 134-43.
64. Giusti B, Abbate R. Response to antiplatelet treatment: From genes to outcome. Lancet 2010; 376(9749): 1278-80.
65. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
66. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithromboticdrug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 3391: 665-71.
67. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J,Emmanuelson H, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98: 1597-603.
68. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in highrisk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126-32.
69. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
70. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al. Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol 2007; 60: 1070. e1-1070.e80.
71. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-47.
72. van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segment ST. Rev Esp Cardiol 2009; 62: e1-e47.
73. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/ American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
74. Silber S, Albertsson P, Fernandez-Avilés F, Camici PG, Colombo A, Hamm C, et al. Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Rev Esp Cardiol 2005; 58: 679-728.
75. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
76. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009; 102: 7-14.
77. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Cytochrome P450 2C19 loss-offunction polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057-64.
78. Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19 loss-offunction polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol 2010; 6: 393-407.
79. US Food and Drug Administration. Plavix (clopidogrel bisulfate) 75mg tablets. May, 2009. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htm
80. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
81. Mega JL, Wiviott SD, Shen L, Walker JR, Simon T, Antmann EA, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010; 376: 1312-9.
82. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
83. Cannon CP, Harrington PA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 2010; 375: 283.
84. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
85. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson C, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009; 373: 723-31.
86. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
87. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a pointofcare assay: A 12-month follow-up. Circulation 2009; 119: 237-242.
88. Mega JL, Simon T, Collet J-P, Anderson JL, Mower CP, Horne BD, et al. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel (abstr). J Am Coll Cardiol 2009; 53(Suppl A): A27.
89. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29.
90. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. The CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41.
91. Gurbel P, Conley P, Andre P, Stephens G, Gretler DD, Jurek M, et al. Oral dosing of PRT060128, a novel direct-acting, reversible P2Y12 antagonist overcomes high platelet reactivity in patients non-responsive to clopidogrel therapy [abstract]. Circulation 2008; 118: S-972.
92. Brandt, J.T., Serebruany, V.L., Winters, K.J. Use of PAR-1/PAR-4 Inhibitors for treating or preventing vascular diseases. US20080214599 (2008).
93. Strony, J.T., Chintala, M. The use of a PAR-1 antagonist in combination with a p2y12adp receptor antagonist for inhibition of thrombosis. WO2011041217 (2011).
94. Zheng, Y., Akbar, H., Williams, D.A., Mazur, W.A. GTPase inhibitors and use thereof for controlling platelet hyperactivity. US20060135542 (2006).
95. Loscalzo, J., Inbal, A. Novel antiplatelet agent. US20020123457 (2002).
96. Kimura, T., Tanaka, N., Sugidachi, A., Konosu, T. Cyclic amine derivative having heteroaryl ring. US7829580 (2010).